Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice

Manuel Monreal1

1Hospital Universitari Germans Trias I Pujol, Badalona, Spain


In recent years, the landscape for management of venous thromboembolism (VTE) has changed with the introduction of the direct oral anticoagulants (DOACs, also known as non-vitamin K antagonist oral anticoagulants).1,2 Current guidelines of antithrombotic therapy recommend the use of dabigatran, rivaroxaban, apixaban or edoxaban in patients with VTE.3 The risk reduction of recurrent VTE with the DOACs is similar to the risk reduction with low-molecular-weight heparin and vitamin K antagonists (VKAs), while the risk of bleeding is less with the DOACs.4–9 Indeed, in an analysis of bleeding events from EINSTEIN, AMPLIFY and HOKUSAI-VTE trials, factor Xa inhibitor associated major bleeding events had a significantly less severe presentation and a similar course compared with VKA.10

However, the pivotal trials where their indication was based on applied strict exclusion criteria, aimed to exclude patients at increased risk for bleeding. They slightly varied from each other, but in general patients were excluded if they had the following: (1) cancer requiring over 6 months of anticoagulant therapy or with a life expectancy of 3 to 6 months; (2) creatinine clearance levels < 30 mL/min; (3) a high risk of bleeding; (4) clinically significant liver disease or (5) pregnancy.

In the Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) real-life registry, one in every five patients (19%) with VTE had at least one of the above-mentioned exclusion criteria.11 Not unexpectedly, these patients had a fourfold higher rate of major bleeding (sixfold higher rate of fatal bleeding) and a threefold higher rate of VTE recurrences (fourfold higher rate of fatal pulmonary embolism [PE]) than those without exclusion criteria. Hence, before prescribing DOACs to VTE patients in real life, the advantages of the DOACs over conventional therapy must be confirmed in real-world population.

In this issue of Thrombosis and Haemostasis, Weycker et al12 report an observational study comparing the effectiveness and safety of apixaban versus warfarin for the long-term therapy of VTE in real life. Investigators used data from four U.S. private health care claims databases from September 2014 to June 2017. After propensity score matching, 17,878 patients receiving long-term therapy with apixaban were compared with 17,878 patients on warfarin. During a mean follow-up of 5 months, patients receiving apixaban had a significantly lower risk for VTE recurrences (hazard ratio [HR]: 0.80), major bleeding (HR: 0.75) and/or clinically relevant non-major bleeding (HR: 0.77) than those on warfarin. Despite some differences in study design, methods and clinical characteristics of the patients (they were older and more likely to have initially presented with PE or to have provoked VTE), these findings are consistent with those in the pivotal Phase III clinical trial (AMPLIFY).7

Strengths of the analysis include that a large number of unselected patients were enrolled. However, there are several limitations, as acknowledged in the manuscript. First, the diagnoses of major bleeding and recurrent VTE were not always confirmed by objective methods, and thus their accuracy is unknown. Second, the authors cannot determine the exact doses and regimens (i.e. once vs. twice daily) of the drugs. In the RIETE registry, one in every two to three patients receiving apixaban was prescribed the drug at doses and/or regimen different from those recommended in the product label.13 This is important since the use of non-recommended doses of DOACs did not reduce the risk of bleeding, but increased the risk of VTE recurrences. Third, since the study does not include full information on mortality, death was not treated as a competing risk, which may influence risks of the outcomes.

The use of DOACs in patients with VTE is progressively increasing over time, but their prescription in patients with exclusion criteria to be recruited in the pivotal trials represents a major challenge due to the lack of evidence on their efficacy and safety. Data from RIETE and PREFER in VTE registries reported that the use of DOACs was less likely in patients with cancer, renal insufficiency or at increased risk for bleeding, and this seems paradoxical since its use has been associated with less bleeding in randomized trials.11,14 It would seem to
be more cost-effective to prescribe safer drugs in patients at increased risk for bleeding. In one of these studies, no VTE patients with severe renal insufficiency (n = 56) or metastatic cancer (n = 45) receiving DOACs for long-term therapy suffered major bleeding, thus suggesting that the DOACs may be at least as safe as standard therapy in these scenarios. Moreover, six pregnant women were prescribed DOACs, when the use of DOACs is formally contraindicated during pregnancy. The International Society on Thrombosis and Haemostasis issued a guidance document that recommended the immediate discontinuation of DOACs after confirmation of pregnancy.

Since randomized clinical trials are not allowed in patients with severe renal insufficiency, pregnancy or at high risk of bleeding, we will need to adjust our prescriptions according to forthcoming evidence from real-life studies.

Conflict of Interest
None.

References